Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 31, Issue 19, 2013, Pages 2404-2412

  Bepler, Gerold ^a,b   Williams, Charles ^b   Schell, Michael J ^b   Chen, Wei ^a   Zheng, Zhong ^b   Simon, George ^d,e   Gadgeel, Shirish ^a   Zhao, Xiuhua ^b   Schreiber, Fred ^c   Brahmer, Julie ^f   Chiappori, Alberto ^b   Tanvetyanon, Tawee ^b   Pinder Schenck, Mary ^b   Gray, Jhanelle ^b   Haura, Eric ^b   Antonia, Scott ^b   Fischer, Juergen R ^g  

^a KARMANOS CANCER INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Watson Clinic   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g Klinikum Loewenstein   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; PROTEIN; RRM1 PROTEIN; UNCLASSIFIED DRUG; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DNA BINDING PROTEIN; DRUG DERIVATIVE; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; MESSENGER RNA; RRM1 PROTEIN, HUMAN; TAXOID; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TUMOR BIOPSY; ADULT; AGED; CANCER STAGING; CHEMISTRY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; FEASIBILITY STUDY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; INTERNATIONAL COOPERATION; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; DNA-BINDING PROTEINS; ENDONUCLEASES; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERNATIONAL COOPERATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; RNA, MESSENGER; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84883115851     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.9783     Document Type: Article

References (27)

1. Druker BJ, Guilhot F, O’Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006
2. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
3. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
4. Kwak EL, Bang Y-J, Camidge R, et al: Ana-plastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
5. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with Braf V600E mutation. N Engl J Med 364:2507-2516, 2011
6. Weiss J, Sos ML, Seidel D, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine 2:1-7, 2010
7. Hammerman PS, Sos ML, Ramos AH, et al: Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery 1:78-89, 2011
8. Sosman JA, Kim KB, Schuchter L, et al: Survival in Braf V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714, 2012
9. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991, 2006
10. Reynolds C, Obasaju C, Schell MJ, et al: Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27:5808-5815, 2009
11. Lord RVN, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291, 2002
12. Rosell R, Scagliotti G, Danenberg KD, et al: Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22:3548-3553, 2003
13. Bepler G, Kusmartseva I, Sharma S, et al: RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24:4731-4737, 2006
14. Ceppi P, Volante M, Novello S, et al: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17:1818-1825, 2006
15. Cobo M, Isla D, Massuti B, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer. J Clin Oncol 25:2747-2754, 2007
16. Simon G, Sharma A, Li X, et al: Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 25:2741-2746, 2007
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
18. Chiappori A, Simon G, Williams C, et al: Phase II study of first line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology 68:382-390, 2005
19. Chiappori AA, Haura E, Rodriguez FA, et al: Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res 14:1464-1469, 2008
20. Zheng Z, Chen T, Li X, et al: The DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800-808, 2007
21. Camp RL, Chung GG, Rimm DL: Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8:1323-1327, 2002
22. O’Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
23. Bepler G, Olaussen KA, Vataire AL, et al: ERCC1 and RRM1 in the International Adjuvant Lung Trial by automated quantitative in situ analysis. Am J Pathol 179:69-78, 2011
24. Zhou J, Oliveira P, Li X, et al: Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines. J Nucleic Acid 2010:1-10, 2010
25. Zhang Y, Li X, Chen Z, et al: Ubiquitination of RRM1 by Ring1B (RNF2) promotes its degradation and nuclear export. Proc Am Assoc Cancer Res 102:3842, 2011
26. Bhagwat NR, Roginskaya VY, Acquafondata MB, et al: Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 69:6831-6838, 2009
27. Ma D, Baruch D, Shu Y, et al: Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC Biotechnology 12:88, 2012